|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||N/A - N/A|
|52-week range||28.22 - 28.22|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||8.97|
|Earnings date||18 Apr 2022|
|Forward dividend & yield||0.77 (2.72%)|
|Ex-dividend date||02 Dec 2021|
|1y target est||N/A|
Bank of America upgraded its rating on pharma and biotech company Moderna from “underperform” to “neutral” along with a new price target of $180 (up from $135) according to a recent BofA Global Research report. BofA cited a “more reasonable valuation” that has come about as being the main reason for the upgrade.
Netflix's unexpectedly poor subscriber growth estimate will likely mean that it takes longer to reach its financial goals than previously expected, a new Bank of America report found.
(Bloomberg) -- The trouble in megacap tech is showing no signs of stopping, and earnings from some of the most-prominent names are adding to investors’ list of worries.Most Read from BloombergA Nor’easter Approaching New York Risks Becoming a Bomb CyclonePowell Backs March Liftoff, Won’t Rule Out Hike Every MeetingStocks Halt Rally as Bond Yields Spike After Fed: Markets WrapAstronomers Spot Never-Before Seen Object at 4,000 Light-Years AwayScientists Identify Factors That Appear Linked to Long